Calidi Biotherapeutics Issues Private Placement Warrant Financing

An announcement from Calidi Biotherapeutics ( (CLDI) ) is now available.

On May 6, 2026, Calidi Biotherapeutics, Inc. issued a warrant to an accredited investor in a private placement, enabling the future purchase of up to 17,391,304 unvested shares of common stock at an exercise price of $0.23 per share. The warrant, first exercisable on September 8, 2026, was structured under exemptions to U.S. securities registration requirements and reflects the company’s continued reliance on private capital.

Under the terms, the investor may agree, but is not obligated, to buy up to $4 million of Calidi’s common stock in registered issuances prior to July 8, 2026, with the warrant vesting proportionally to any such completed share sales. This financing structure offers Calidi a flexible mechanism to raise equity while potentially diluting existing shareholders, and signals ongoing efforts to secure funding amid regulatory constraints in the capital markets.

Spark’s Take on CLDI Stock

According to Spark, TipRanks’ AI Analyst, CLDI is a Neutral.

The score is primarily constrained by weak financial performance (minimal revenue, large losses, and heavy cash burn) and bearish technicals (price below key moving averages and negative MACD). Balance-sheet improvement and ongoing pipeline progress provide partial support, but dilution and continued financing needs remain meaningful risks.

To see Spark’s full report on CLDI stock, click here.

More about Calidi Biotherapeutics

Calidi Biotherapeutics, Inc. is a biotechnology company focused on developing therapeutic products using its expertise in biologics and oncology. The company operates in the life sciences sector and accesses capital markets to fund its research and development activities and broader corporate operations.

Average Trading Volume: 3,629,361

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.36M

See more data about CLDI stock on TipRanks’ Stock Analysis page.